The CDH1 -160C/A polymorphism is associated with breast cancer: evidence from a meta-analysis

World J Surg Oncol. 2016 Jun 27;14(1):169. doi: 10.1186/s12957-016-0927-0.

Abstract

Background: Numerous epidemiological studies have evaluated the association between the CDH1 -160C/A polymorphism and the risk of breast cancers. However, these studies have yielded conflicting results. To derive a more precise estimation of this association, this meta-analysis was conducted.

Methods: A comprehensive search using the keywords "CDH1," "E-Cadherin," "polymorphism," "SNP," and "variant" combined with "breast," "cancer," "tumor," or "carcinomas" was conducted. Pooled odds ratios (ORs) with 95 % confidence intervals (CIs) were appropriately calculated using a fixed effect or random effect model. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2009 checklist was used for this meta-analysis.

Results: Four publications including five studies were identified. It was found that the CDH1 -160C/A polymorphism was significantly associated with breast cancer risk in the dominant model (CA + AA vs. CC: OR = 1.207, 95 % CI = 1.031-1.412, P = 0.019).

Conclusions: Our meta-analysis demonstrated that the -160C/A polymorphism in the CDH1 gene might contribute to breast cancer susceptibility. Further investigations using a much larger sample including different ethnicities are still needed to verify this association.

Keywords: Breast cancer; CDH1; Meta-analysis; Polymorphism.

Publication types

  • Meta-Analysis

MeSH terms

  • Antigens, CD
  • Breast Neoplasms / genetics*
  • Cadherins / genetics*
  • Female
  • Genetic Predisposition to Disease*
  • Humans
  • Polymorphism, Single Nucleotide / genetics*
  • Risk Factors

Substances

  • Antigens, CD
  • CDH1 protein, human
  • Cadherins